| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patient...
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.
U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medi...
Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now...
WAINUA was approved by the FDA in December 2023 for the treatment of the polyneuropathy of hereditary transthyretin-mediated am...
https://www.nbcnews.com/now/video/disease-experts-predict-a-small-rise-in-covid-cases-this-summer-211393605953 Disease experts ...
AstraZeneca aims to boost its revenue from $45.8 billion in 2023 to $80 billion by 2030. Key growth drivers include expanding o...
